{"entity": "researcher", "timestamp": "2026-09-28T23:50:59.777Z", "family": "Kolberg", "given": "Matthias", "initials": "M", "orcid": "0000-0001-8288-5364", "affiliations": ["Department of Molecular Oncology, Institute for Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Norway.", "K.G. Jebsen Colorectal Cancer Research Centre, Clinic for Cancer Medicine, Oslo University Hospital, Norway."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/efd844ab277047d38f0cc9d9a8216250.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/efd844ab277047d38f0cc9d9a8216250"}}, "publications": [{"entity": "publication", "iuid": "353c589cc2fd49779557600155b35592", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/353c589cc2fd49779557600155b35592.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/353c589cc2fd49779557600155b35592"}}, "title": "Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.", "authors": [{"family": "Bruun", "given": "Jarle", "initials": "J"}, {"family": "Sveen", "given": "Anita", "initials": "A"}, {"family": "Barros", "given": "Rita", "initials": "R"}, {"family": "Eide", "given": "Peter W", "initials": "PW"}, {"family": "Eilertsen", "given": "Ina", "initials": "I"}, {"family": "Kolberg", "given": "Matthias", "initials": "M", "orcid": "0000-0001-8288-5364", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/efd844ab277047d38f0cc9d9a8216250.json"}}, {"family": "Pellinen", "given": "Teijo", "initials": "T"}, {"family": "David", "given": "Leonor", "initials": "L"}, {"family": "Svindland", "given": "Aud", "initials": "A"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Guren", "given": "Marianne G", "initials": "MG"}, {"family": "Nesbakken", "given": "Arild", "initials": "A"}, {"family": "Almeida", "given": "Raquel", "initials": "R"}, {"family": "Lothe", "given": "Ragnhild A", "initials": "RA"}], "type": "journal article", "published": "2018-09-00", "journal": {"title": "Mol Oncol", "issn": "1878-0261", "volume": "12", "issue": "9", "pages": "1639-1655", "issn-l": "1574-7891"}, "abstract": "We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colorectal cancer (CRC) according to disease stage and chemotherapy sensitivity in preclinical models. CDX2 expression was evaluated in 1045 stage I-IV primary CRCs by gene expression (n = 403) or immunohistochemistry (n = 642) and in relation to 5-year relapse-free survival (RFS), overall survival (OS), and chemotherapy. Pharmacogenomic associations between CDX2 expression and 69 chemotherapeutics were assessed by drug screening of 35 CRC cell lines. CDX2 expression was lost in 11.6% of cases and showed independent poor prognostic value in multivariable models. For individual stages, CDX2 was prognostic only in stage IV, independent of chemotherapy. Among stage I-III patients not treated in an adjuvant setting, CDX2 loss was associated with a particularly poor survival in the BRAF-mutated subgroup, but prognostic value was independent of microsatellite instability status and the consensus molecular subtypes. In stage III, the 5-year RFS rate was higher among patients with loss of CDX2 who received adjuvant chemotherapy than among patients who did not. The CDX2-negative cell lines were significantly more sensitive to chemotherapeutics than CDX2-positive cells, and the multidrug resistance genes MDR1 and CFTR were significantly downregulated both in CDX2-negative cells and in patient tumors. Loss of CDX2 in CRC is an adverse prognostic biomarker only in stage IV disease and appears to be associated with benefit from adjuvant chemotherapy in stage III. Early-stage patients not qualifying for chemotherapy might be reconsidered for such treatment if their tumor has loss of CDX2 and mutated BRAF.", "doi": "10.1002/1878-0261.12347", "pmid": "29900672", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6120232"}], "notes": [], "created": "2019-01-17T14:01:49.883Z", "modified": "2026-09-23T09:19:19.508Z"}, {"entity": "publication", "iuid": "32449e30fec643bd85167a3be795a9b9", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/32449e30fec643bd85167a3be795a9b9.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/32449e30fec643bd85167a3be795a9b9"}}, "title": "Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.", "authors": [{"family": "Kolberg", "given": "Matthias", "initials": "M", "orcid": "0000-0001-8288-5364", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/efd844ab277047d38f0cc9d9a8216250.json"}}, {"family": "Bruun", "given": "Jarle", "initials": "J"}, {"family": "Murum\u00e4gi", "given": "Astrid", "initials": "A"}, {"family": "Mpindi", "given": "John P", "initials": "JP"}, {"family": "Bergsland", "given": "Christian H", "initials": "CH"}, {"family": "H\u00f8land", "given": "Maren", "initials": "M"}, {"family": "Eilertsen", "given": "Ina A", "initials": "IA"}, {"family": "Danielsen", "given": "Stine A", "initials": "SA"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Lothe", "given": "Ragnhild A", "initials": "RA"}], "type": "journal article", "published": "2017-09-00", "journal": {"title": "Mol Oncol", "issn": "1878-0261", "volume": "11", "issue": "9", "pages": "1156-1171", "issn-l": "1574-7891"}, "abstract": "Patients with malignant peripheral nerve sheath tumor (MPNST), a rare soft tissue cancer associated with loss of the tumor suppressor neurofibromin (NF1), have poor prognosis and typically respond poorly to adjuvant therapy. We evaluated the effect of 299 clinical and investigational compounds on seven MPNST cell lines, two primary cultures of human Schwann cells, and five normal bone marrow aspirates, to identify potent drugs for MPNST treatment with few side effects. Top hits included Polo-like kinase 1 (PLK1) inhibitors (volasertib and BI2536) and the fluoronucleoside gemcitabine, which were validated in orthogonal assays measuring viability, cytotoxicity, and apoptosis. DNA copy number, gene expression, and protein expression were determined for the cell lines to assess pharmacogenomic relationships. MPNST cells were more sensitive to BI2536 and gemcitabine compared to a reference set of 94 cancer cell lines. PLK1, RRM1, and RRM2 mRNA levels were increased in MPNST compared to benign neurofibroma tissue, and the protein level of PLK1 was increased in the MPNST cell lines compared to normal Schwann cells, indicating an increased dependence on these drug targets in malignant cells. Furthermore, we observed an association between increased mRNA expression of PLK1, RRM1, and RRM2 in patient samples and worse disease outcome, suggesting a selective benefit from inhibition of these genes in the most aggressive tumors.", "doi": "10.1002/1878-0261.12086", "pmid": "28556483", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC5579334"}], "notes": [], "created": "2018-12-05T12:56:29.769Z", "modified": "2026-09-23T10:57:01.513Z"}]}